IL219179A0 - Treating neurotoxicity associated with combinations of 5--fu or its prodrugs and dpd inhibitors - Google Patents

Treating neurotoxicity associated with combinations of 5--fu or its prodrugs and dpd inhibitors

Info

Publication number
IL219179A0
IL219179A0 IL219179A IL21917912A IL219179A0 IL 219179 A0 IL219179 A0 IL 219179A0 IL 219179 A IL219179 A IL 219179A IL 21917912 A IL21917912 A IL 21917912A IL 219179 A0 IL219179 A0 IL 219179A0
Authority
IL
Israel
Prior art keywords
prodrugs
combinations
neurotoxicity associated
dpd inhibitors
treating neurotoxicity
Prior art date
Application number
IL219179A
Other languages
English (en)
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Publication of IL219179A0 publication Critical patent/IL219179A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL219179A 2009-10-14 2012-04-15 Treating neurotoxicity associated with combinations of 5--fu or its prodrugs and dpd inhibitors IL219179A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25144909P 2009-10-14 2009-10-14
PCT/US2010/052734 WO2011047195A1 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors

Publications (1)

Publication Number Publication Date
IL219179A0 true IL219179A0 (en) 2012-06-28

Family

ID=43466528

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219179A IL219179A0 (en) 2009-10-14 2012-04-15 Treating neurotoxicity associated with combinations of 5--fu or its prodrugs and dpd inhibitors

Country Status (14)

Country Link
US (1) US8658618B2 (enExample)
EP (1) EP2488182B1 (enExample)
JP (2) JP2013508293A (enExample)
KR (1) KR20120127709A (enExample)
CN (1) CN102811721A (enExample)
AU (1) AU2010306698B2 (enExample)
BR (1) BR112012008951A2 (enExample)
CA (1) CA2777546C (enExample)
CO (1) CO6541596A2 (enExample)
EA (1) EA201270551A1 (enExample)
ES (1) ES2644237T3 (enExample)
IL (1) IL219179A0 (enExample)
MX (1) MX2012004383A (enExample)
WO (1) WO2011047195A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
WO2024123736A1 (en) * 2022-12-06 2024-06-13 Elion Oncology, Inc. Combined use of eniluracil and capecitabine for treating cancer
AR133242A1 (es) * 2023-07-13 2025-09-10 Processa Pharmaceuticals Inc Métodos de personalización del tratamiento contra el cáncer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687599A (en) 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
ATE161722T1 (de) * 1990-07-19 1998-01-15 Wellcome Found Enzyminaktivatoren
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法

Also Published As

Publication number Publication date
EA201270551A1 (ru) 2012-12-28
BR112012008951A2 (pt) 2019-09-24
CA2777546C (en) 2019-11-05
MX2012004383A (es) 2012-08-23
EP2488182A1 (en) 2012-08-22
EP2488182B1 (en) 2017-07-19
CN102811721A (zh) 2012-12-05
US8658618B2 (en) 2014-02-25
KR20120127709A (ko) 2012-11-23
AU2010306698A1 (en) 2012-05-17
AU2010306698B2 (en) 2016-05-26
JP2013508293A (ja) 2013-03-07
CA2777546A1 (en) 2011-04-21
ES2644237T3 (es) 2017-11-28
JP2016014051A (ja) 2016-01-28
US20110130359A1 (en) 2011-06-02
WO2011047195A1 (en) 2011-04-21
CO6541596A2 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
ZA201201365B (en) Plant pathogen inhibitor combinations and methods of use
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
IL218316A0 (en) Combination therapy with nanoparicle compositions of taxane and hedgehog inhibitors
IL214403A0 (en) Novelcell lines and methods
ZA201105933B (en) Methods of diagnosing and treating dysphagia
IL239918A0 (en) Preparations for the treatment of colitis
ZA201105758B (en) Methods of reducing the proliferation and viability of microbial agents
ZA201204700B (en) Optimized endonucleases and uses thereof
IL218778A0 (en) Lysine specific demethylase - 1 inhibitors and their use
PT2389352T (pt) Inibidores de arginase e métodos de utilização
ZA201200263B (en) Compounds and methods for treating influenza
PL2271868T3 (pl) Świnka do wirowego rozpraszania inhibitora i sposób
SI2271626T1 (sl) Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
EP2493309A4 (en) METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
SG11201401949YA (en) Nadph oxidase 4 inhibitors and use thereof
ZA201104259B (en) Combinations comprising methotrexate and dhodh inhibitors
PT2498731T (pt) Métodos de tratamento ou prevenção de uma trombose de endoprótese
EP2462200A4 (en) BIODEGRADABLE PROTECTIVE COVERS AND METHODS OF USE
IL215583A0 (en) Methods for preventing and/or treating lysosomal storage disorders
PL2987803T3 (pl) Warianty SAP i ich zastosowanie
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
IL214757A0 (en) Compositions and methods to prevent and/or treat cancer with pa-card
PL2575858T3 (pl) Sposoby leczenia zespołu nerczycowego
GB0906643D0 (en) Detection of bacteria and fungi
EP2486102A4 (en) SURFACE-FINISHED STRUCTURES AND CORRESPONDING METHODS